• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research

    1/23/25 10:35:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email

    New York, United States, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Gene synthesis is a synthetic biology technique used in the laboratory to create artificial genes. In contrast to molecular cloning and polymerase chain reactions, this method uses solid-phase DNA synthesis (PCR). Gene synthesis is utilized for molecular cloning, the production of fusion proteins, and attaining sufficient protein expression levels. Compared to conventional molecular cloning techniques, the gene synthesis service provides unparalleled customization from top to bottom while saving time and money. Gene synthesis is the chemical in vitro synthesis of double-stranded DNA molecules. It is a biotechnology tool that has a significant impact on synthetic biology.

    Download Free Sample Report PDF @ https://straitsresearch.com/report/gene-synthesis-market/request-sample

    Market Dynamics

    Growing Adoption of Gene Therapy Techniques in Molecular Biology and Latest Developments in the Gene Synthesis Process Drive the Global Market

    In molecular biology and gene therapy, the development and application of numerous cutting-edge gene-editing techniques represent a significant advancement. Consequently, significant progress has been made in developing gene therapy for use in molecular biology. Recent technological advancements have produced well-designed goods and services, such as molecular separation, gene synthesis on microchips, and protein purification, which have contributed to the expansion of life science research. Gene synthesis has been acknowledged as an efficient and cost-effective alternative to conventional cloning and mutagenesis techniques. These dependable and efficient solutions in developed nations drive federal funding for various academic research projects and the market.

    Growing Population with Genetic and Chronic Disorders Creates Tremendous Opportunities

    One of the factors that will positively impact the gene synthesis market is the rising public demand for targeted and personalized medicine. In addition, increasing government, private, and public investment in synthetic biology is anticipated to speed up the global gene synthesis market and create lucrative business opportunities for key players in the coming years.

    Regional Analysis

    North America is the largest global gene synthesis market shareholder due to significant players and government initiatives in training and implementing synthetic biology programs. The increasing use of gene editing and synthesis-related techniques by drug and diagnostic developers in the United States fosters regional market expansion. Additionally, regulatory approval and commercialization of synthetic gene products in the region have contributed to the expansion of the market. 

    Ask for Customization @ https://straitsresearch.com/report/gene-synthesis-market/request-sample

    Key Highlights

    • The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033).
    • Based on the method, the market is divided into solid-phase, chip-based, and PCR-based enzyme synthesis. The solid-phase segment accounts for the largest revenue share due to the highest adoption rate over the past few years.
    • Based on service, the market is categorized into antibody DNA synthesis, viral DNA synthesis, and others. The antibody DNA synthesis segment is the most dominant due to the large number of market participants providing services for antibody DNA synthesis.
    • Based on application, the market is bifurcated into gene and cell therapy development, vaccine development, disease diagnosis, and others. The development of gene and cell therapies accounted for the largest revenue share
    • Based on end-user, the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations. The academic and governmental research institutes segment is anticipated to dominate the market.
    • North America is the largest global gene synthesis market shareholder due to significant players and government initiatives in training and implementing synthetic biology programs.

    Competitive Players

    1. GenScript
    2. Brooks Automation, Inc. (GENEWIZ)
    3. Boster Biological Technology
    4. Twist Bioscience
    5. ProteoGenix
    6. Biomatik
    7. ProMab Biotechnologies, Inc.
    8. Thermo Fisher Scientific, Inc.
    9. Integrated DNA Technologies, Inc.
    10. OriGene Technologies, Inc.

    Recent Developments

    • June 2022- Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ildong Pharmaceutical announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology.
    • July 2022- Twist Bioscience Opened New Twist Boston Location to Expand Antibody Discovery Capacity. Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the opening of its new Twist Boston location in Quincy, Massachusetts.

    Segmentation

    By Method 

    • Solid-phase Synthesis
    • Chip-based Synthesis
    • PCR-based Enzyme Synthesis

    By Service

    • Antibody DNA Synthesis
    • Viral DNA Synthesis
    • Others

    By Application 

    • Gene and Cell Therapy Development
    • Vaccine Development
    • Disease Diagnosis
    • Others

    By End-User

    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

    By Region

    • North America
    • Europe
    • Asia Pacific
    • Middle East And Africa
    • Latin America

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/gene-synthesis-market/segmentation

    About Straits Research Pvt. Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    Phone: +1 646 905 0080 (U.S.)

    +44 203 695 0070 (U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $TWST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    11/4/2025$41.00Overweight
    Stephens
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    More analyst ratings

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Werner Robert F. sold $11,421 worth of shares (246 units at $46.43), decreasing direct ownership by 0.45% to 54,799 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    3/10/26 4:06:25 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP of Human Resources Green Paula sold $43,408 worth of shares (935 units at $46.43), decreasing direct ownership by 0.75% to 124,401 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    3/10/26 4:05:13 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Cho Dennis sold $19,731 worth of shares (425 units at $46.43), decreasing direct ownership by 0.31% to 138,257 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    3/10/26 4:05:15 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Twist Bioscience with a new price target

    Stephens initiated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $41.00

    11/4/25 7:44:48 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Twist Bioscience with a new price target

    Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:32:53 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Twist Bioscience with a new price target

    Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

    6/4/24 7:44:10 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twist Bioscience to Present at Upcoming Investor Conferences

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 in Boston, MA; fireside chat at 1:50 pm Eastern Time Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10 in Miami, FL; fireside chat at 3:00 pm Eastern Time Leerink Global Healthcare Conference on Wednesday, March 11 in Miami, FL; fireside chat at 8:40 am Eastern Time The fireside chats will be webcast

    2/18/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

    Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market New kits compatible with additional Twist NGS Applications tools for complete target enrichment and WGS library prep workflows Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist Tr

    2/10/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    3/6/26 2:00:02 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 10-Q/A filed by Twist Bioscience Corporation

    10-Q/A - Twist Bioscience Corp (0001581280) (Filer)

    2/26/26 4:19:15 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    2/23/26 3:18:24 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    View All

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

    1/5/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/5/24 6:07:26 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Financials

    Live finance-specific insights

    View All

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's

    2/2/26 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the fiscal 2026 first quarter preliminary, unaudited revenue, or click https://investors.twistbioscience.com/events-and-presentations. Twist will issue its financial results for the first quarter of fiscal 2026 before the opening of the market on February 2, 2026, and will hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Easte

    1/12/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care